ClinicalTrials.gg
RecruitingNCT07374562STAR-COUpdated Feb 9, 2026

Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial

An interventional study of Stellate Ganglion Block (Bupivacaine) and placebo saline injection in Long COVID, sponsored by Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Planned enrollment
22nd of 33
40 · median 82
Started
2026
with 4 others
No phase
23 of 40
6 open now
Primary completion
2027-02
later than 7 of 16 live
Registered
37th of 40
by date
Lead sponsor
2 of 40
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 22nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2026, is one of 23 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 37th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle. After the intervention, participants are followed for 26 weeks with scheduled evaluations that include symptom questionnaires and functional tests.

The study assesses changes in functional status, fatigue, cognitive complaints, quality of life, dyspnea, lower-limb endurance, and orthostatic tolerance over time. Safety is monitored throughout all follow-up visits. Approximately 40 participants meeting predefined eligibility criteria will be enrolled. This trial seeks to determine whether a single stellate ganglion block has an effect on persistent long-COVID symptoms compared with placebo.The results will help determine the therapeutic value of SGB in the management of long COVID and inform future research and clinical practice.

03

Conditions studied

  • Long COVID

Keywords

  • Long COVID
  • Stellate Ganglion Block
  • Bupivacaine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Positive COVID-19 test confirmed by RT-PCR, antibody test, or antigen test at least 3 months prior to randomization, OR presumed COVID-19 evaluated by the site investigator (no positive test required) with an acute illness occurring after October 15, 2019 and at least 3 months prior to randomization.
  • Persistent symptoms ≥12 weeks after onset of acute COVID-19 AND symptoms lasting at least 2 months. The onset date is defined as the earliest of: date of first positive test, date of first symptoms
  • Post-COVID Functional Status Scale score ≥2.
  • Persistent dyspnea ≥2/4 on the mMRC scale at least 12 weeks post-infection.
  • Persistent COVID-19-related symptoms at the time of randomization.
  • If taking medications for fatigue or cognition (e.g., sildenafil, modafinil, armodafinil, guanfacine, N-acetylcysteine, stimulants for ADHD), these must have been initiated and stable for ≥4 weeks prior to randomization. Participants are asked not to stop or alter these medications during the study if possible.
  • Able and willing to provide written .
  • Able to read and understand French.

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of myalgic encephalomyelitis (ME) or fibromyalgia
  • Being on sick leave or disability at the time of the original acute COVID-19 infection.
  • Pregnancy or breastfeeding.
  • Myocardial infarction within the last 12 weeks.
  • Use of anticoagulant therapy.
  • Glaucoma.
  • Emphysema requiring home oxygen.
  • Cardiac conduction abnormalities.
  • Known to bupivacaine.
  • Previous stellate ganglion block (SGB) procedure.
  • Any condition that, in the judgment of the medical investigator, makes the patient not a candidate for the proposed treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Stellate Ganglion Block with Bupivacaine

    Participant receives a right-sided stellate ganglion block under ultrasound guidance, using bupivacaine, performed by an anesthesiologist.

    Procedure: Stellate Ganglion Block (Bupivacaine)

  • Placebo comparator
    Placebo Neck Injection

    Participant receives a saline injection into the sternocleidomastoid muscle under the same conditions.

    Procedure: placebo saline injection

Interventions

  • ProcedureStellate Ganglion Block (Bupivacaine)

    A single ultrasound-guided stellate ganglion block is administered on the right side of the neck under sterile conditions by an anesthesiologist. The needle is positioned between the longus colli muscle and the right carotid artery, and 7 mL of 0.5% bupivacaine is injected. Correct placement is verified by ultrasound and confirmed clinically by the expected appearance of Claude Bernard-Horner syndrome following the injection. Participants are observed for approximately 30 minutes after the procedure.

  • Procedureplacebo saline injection

    A single placebo injection of 6-8 mL of 0.9% normal saline is administered into the right sternocleidomastoid muscle. The procedure uses the same patient positioning, sterile preparation, and ultrasound guidance as the active arm; however, the needle is intentionally placed in the muscle, away from the stellate ganglion, and does not produce a stellate ganglion block (i.e., cannot cause Claude Bernard-Horner syndrome).

06

What researchers measure

Primary outcomes

  1. Post-COVID-19 Functional Status Scale (PCFS)

    The PCFS measures limitations in daily functioning related to persistent post-COVID-19 symptoms. Scores range from 0 (no functional limitation) to 4 (severe functional limitation). Assesses changes in functional status over time.

    Time frame: 4 weeks after the intervention

  2. Fatigue Severity Scale (FSS)

    The FSS is a validated 9-item questionnaire assessing the impact of fatigue on daily activities, motivation, and functioning. Each item is scored from 1 to 7; higher scores indicate greater fatigue severity. Clinically significant change is defined as ≥0.45 points.

    Time frame: 4 weeks after the intervention

  3. Brain Fog Scale (BFS)

    The BFS is a 23-item questionnaire evaluating cognitive symptoms associated with Long COVID, including mental fatigue, cognitive clarity, logical thinking, and concentration. Total scores range from 0 to 92, with higher scores indicating more severe cognitive impairment.

    Time frame: 4 weeks after the intervention

Secondary outcomes

  1. Health-Related Quality of Life (SF-36)

    The SF-36 is a validated 36-item questionnaire assessing eight domains of health-related quality of life, including physical functioning, limitations due to physical or emotional problems, pain, general health, vitality, social functioning, and mental health. Higher scores reflect better perceived health and functioning.

    Time frame: 4 weeks after the intervention

  2. Dyspnea Severity (mMRC Scale)

    The modified Medical Research Council (mMRC) Dyspnea Scale is a 0-4 grading system that assesses the degree to which breathlessness limits daily activities. Higher grades indicate greater functional limitation due to dyspnea. It is the only validated French-language scale measuring dyspnea in daily activities.

    Time frame: 4 weeks after the intervention

  3. Lower-Limb Muscle Endurance (1-Minute Sit-to-Stand Test)

    The 1-Minute Sit-to-Stand Test (1STST) measures lower-limb muscular endurance by counting the number of sit-to-stand repetitions a participant completes in one minute from a standard chair without armrests. It is reliable, sensitive, and well-tolerated in populations with impaired physical capacity. Higher counts indicate better endurance.

    Time frame: 4 weeks after the intervention

  4. Orthostatic Intolerance (NASA Lean Test)

    The NASA Lean Test assesses orthostatic intolerance by measuring heart rate and blood pressure changes during 10 minutes of standing with the back supported against a wall. Results help identify symptoms such as dizziness, palpitations, or light-headedness related to positional changes. If a participant cannot complete 10 minutes, the test is still considered valid.

    Time frame: 4 weeks after the intervention

07

Study locations

1 of 1 sites recruiting
  • Centre hospitalier affilié universitaire régional
    Trois-Rivières, Quebec G8Z 3R9, Canada
    Recruiting
    • Marie-Claude Lehoux, Master's degree · Contactmarie-claude.lehoux@ssss.gouv.qc.ca · 819 697-3333
    • Éva Mathieu, Ph.D · Contacteva.mathieu@ssss.gouv.qc.ca · 819-697-3333
    • David Hakim, MD · Principal investigator
    • Andrés Felipe Fil Blanco, MD · Principal investigator
    • Magali Brousseau-Foley, MD, Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374562
Lead sponsor
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Responsible party
Marie-Claude Lehoux (Principal Investigator, Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec) — Principal investigator
First posted
Jan 29, 2026
Start date
Feb 5, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Marie-Claude Lehoux, Master's degree
Contact
marie-claude.lehoux@ssss.gouv.qc.ca
819 697-3333 ext. 60753
Éva Mathieu, Ph.D
Contact
eva.mathieu@ssss.gouv.qc.ca
819 697-3333 ext. 60756

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion